Acadia Healthcare Company, Inc. (ACHC) AI Stock Analysis

Acadia Healthcare Company, Inc. delivers comprehensive behavioral healthcare services across the United States and Puerto Rico. Specializing in a wide range of mental health treatments, Acadia operates through various settings such as inpatient psychiatric facilities, specialty treatment facilities, residential treatment centers, eating disorder facilities, and outpatient clinics. These diverse care environments allow Acadia to address the unique needs of each patient, providing personalized and effective treatment plans. Founded in 2005 and headquartered in Franklin, Tennessee, the company operates a network of facilities supported by a team of experienced professionals, including psychiatrists, psychologists, nurses, and therapists delivering evidence-based care.

Acadia Healthcare grew annual revenue from $2.31B in FY2021 to $3.31B in FY2025, reflecting a 5-year revenue CAGR of 9.7%. However, gross margin compressed from 96.1% in FY2021 to 17.6% in FY2025, while operating margin fell from 17.9% to 11.7%. Net income swung from $190.6M in FY2021 to -$1.10B in FY2025, resulting in a net margin of -33.3%. For the trailing twelve months, revenue reached $3.37B with an operating margin of 10.1% and diluted EPS of -$12.42. In the latest quarter ended June 30, 2026, quarterly revenue fell 0.4% year-over-year, while quarterly earnings dropped 63.6%.

As of June 30, 2026, Acadia Healthcare held $171.3M in cash and short-term investments compared to $2.56B in total debt, bringing net debt to $2.39B. The company closed the quarter with a current ratio of 1.57 and a debt-to-equity ratio of 1.30 on shareholders' equity of $1.98B. In FY2025, operating cash flow stood at $131.9M while capital expenditures of $571.8M resulted in free cash flow of -$439.9M. During that fiscal year, Acadia spent $50.0M on share buybacks, and its share count rose 0.4% over 5 years.

ACHC trades at a forward P/E of 15.2x, below the 17.3x forward P/E median of its US-listed Healthcare peers. Its enterprise value stands at $5.05B with an EV/EBITDA of 9.5x, compared to the peer median of 12.0x, and its price-to-sales multiple is 0.8x against the peer group median of 4.1x. Over the past year, the stock returned 21.2%, outperforming the S&P 500 (SPY) return of 16.8%. However, its 5-year return of -47.3% trails the S&P 500 return of 83.0%.

Wall Street coverage includes 6 Strong Buy, 2 Buy, 5 Hold, 1 Sell, and 0 Strong Sell ratings. The mean price target of $33.79 represents a 12.7% upside over the October 16, 2026 closing price of $29.98. For the fiscal year ending December 31, 2026, consensus estimates project EPS of $1.55 on revenue of $3.43B. For the following fiscal year, 13 analysts project EPS of $1.85 on revenue of $3.63B. Acadia has beaten EPS estimates in 3 of the last 4 quarters, and its next earnings report is scheduled for November 4, 2026.

This page is an AI-written research summary of Acadia Healthcare Company, Inc. (ACHC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ACHC income statement, ACHC balance sheet, ACHC key metrics, ACHC analyst forecast, ACHC chart. See the ACHC stock overview for the latest quote and news.